One of the biggest challenges of the world in this 21st century is to cure HIV-AIDS. In Present scenario different antiviral drugs are available in the market to reduce the worse condition and manage improved survival rate. These drugs are manageable but their bioavailability, lower permeability and poor half life of the drugs have limitations. If the drug is preferred in higher dosage in AIDS patients, the drug leads to toxicity and adverse effects to patients and increase resistant against HIV & if the drug is preferred in lower dose along with nano carriers it will reach the target area for beneficial effect, therefore drugs Lacking of Knowledge in Potent Drug delivery systems is due to instability, chemical degradation and tissue barrier difficulties are reasons to reach drug target successfully. In this scenario Nanotechnology based antiretroviral drugs delivery holds drug and will provide to cure AIDS. Nanotechnology based deliver system Nanocarriers like Liposomes, dendrimers, Nanoparticles, Polymeric Micelles, Nanovesicles, Nanoemulsion provide the way to deliver drug to targeting tissue. Nanobased carriers revolutionized the field of Pharmaceutics and Pharmaco Kinetic’s in target drug delivery. The present study depicts nano based ARV drug provides increase efficiency with less adverse effects to control HIV. Like same way we can provide and increase nanobased drug delivery capacity to other available HIV drugs.
Part of the book: AIDS Updates
Tuberculosis is an infectious disease spread through the air that is treated with a combination of drugs. Compliance to long-term antituberculosis therapy is vital for sustaining adequate blood drug level. Inadequate medical management of patients is a major factor in the emergence and dissemination of drug-resistant Mycobacterium TB strains. The necessity to understand the context of individual and collective health when considering tuberculosis treatment remains a difficulty. Furthermore, when it comes to treatment success, social and economic factors have been demonstrated to be aspects that must be considered. Because of the poor, expensive, ineffective, and toxic alternatives to first-line medications, the therapeutic approach for drug-resistant tuberculosis is complicated. New antituberculosis medications (bedaquiline and delamanid) have recently been licenced by health authorities; however, they do not constitute a definitive answer for the clinical management of drug-resistant tuberculosis forms, especially in middle-income countries where drug resistance is common (China, India, and former Soviet Union countries). There is an immediate need for new research and development initiatives. To sustain both new and ancient therapeutic choices, public health policies are essential. We did a thorough review of national and international literature on tuberculosis treatment in India in recent years with the goal of providing advice to health care providers based on the scenario.
Part of the book: Dosage Forms